ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2305

Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry

Alexis Ogdie1, Ellen Romich2, Brian Coburn3, Rebecca Schumacher4 and Kaleb Michaud5, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, 2University of Pennsylvania, Media, PA, 3Hospital of the University of Pennsylvania, Philadelphia, PA, 4FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 5University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2025

Keywords: Health Services Research, population studies, Psoriatic arthritis, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with psoriasis and psoriatic arthritis (PsA) are at increased risk for metabolic comorbidities and poorer long-term outcomes compared to the general population. Identifying patients at risk for adverse outcomes can facilitate targeted interventions to improve quality of life.This study aimed to evaluate the risk of hospitalization and emergency department (ED) visits among adults with psoriatic disease and identify predictors of these outcomes.

Methods: We utilized data from the Forward Psoriasis Registry, a cohort recruited from U.S. dermatology practices, two academic institutions, and the Forward registry website. Participants enrolled between August 2023 and March 2025 completed baseline and monthly surveys, with longer assessments every six months. Surveys included comorbidity data, psoriasis severity (measured by the Patient Report of Extent of Psoriasis Involvement [PREPI]), patient-reported outcomes (Psoriasis Symptoms and Signs Diary [PSSD]), medication changes, and adverse events, including hospitalization and ED visits. Participants with psoriasis (with or without PsA) who completed enrollment and had at least one follow-up visit were included. We report baseline demographics, disease characteristics, treatments, and comorbidities. Cox proportional hazards models were used to identify predictors of hospitalization and ED visits, with a multivariable model developed using purposeful selection modeling.

Results: ong 2,606 enrollees, 1,354 had at least one follow-up visit, with a mean follow-up time of 213 days (SD 145). The cohort had a mean age of 51 years (SD 16), 66% were female, and 56% were from the southern United States. Most had mild to moderate psoriasis (23% with < 1% BSA, 40% with 1-2% BSA, 30% with 3-10% BSA, and 6% with >10% BSA). A total of 135 participants experienced an ED visit (incidence 0.18 per person-year), and 59 were hospitalized (incidence 0.08 per person-year). Predictors of ED visits and hospitalization were similar. Lower psoriasis severity (< 1% BSA) was associated with the lowest risk for both outcomes. Higher PSSD scores, depression, and female sex were significantly associated with increased risk. Although a diagnosis of ADHD was initially significant, it was removed from the final model due to lack of consistency.

Conclusion: In this cohort with psoriatic disease, predictors of hospitalization and ED visits included higher PSSD scores, depression, and female sex. The PSSD, a patient-reported outcome, demonstrated predictive value beyond the psoriasis severity measured by body surface area, underscoring the importance of patient-reported outcomes in assessing disease impact.

Supporting image 1Table 1. Baseline Characteristics

Supporting image 2Table 2. Univariable and multivariable models


Disclosures: A. Ogdie: AbbVie, 5, Amgen, 5, 11, Bristol Myers Squibb, 5, Celgene, 5, CorEvitas, 2, Eli Lilly, 5, Novartis, 5, 11, Pfizer, 5, 11; E. Romich: Lungpacer Medical, Inc., 11, Teva Pharmaceuticals, 12, Spouse employment; B. Coburn: None; R. Schumacher: None; K. Michaud: None.

To cite this abstract in AMA style:

Ogdie A, Romich E, Coburn B, Schumacher R, Michaud K. Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/predictors-of-hospitalization-and-emergency-department-visits-among-patients-with-psoriatic-disease-insights-from-the-forward-psoriasis-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-hospitalization-and-emergency-department-visits-among-patients-with-psoriatic-disease-insights-from-the-forward-psoriasis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology